- Home
- CNI vs ZTS Comparison
CNI vs ZTS Comparison
Compare CNI & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNI
- ZTS
- Stock Information
- Founded
- CNI 1919
- ZTS 1952
- Country
- CNI Canada
- ZTS United States
- Employees
- CNI N/A
- ZTS N/A
- Industry
- CNI
- ZTS Biotechnology: Pharmaceutical Preparations
- Sector
- CNI
- ZTS Health Care
- Exchange
- CNI Nasdaq
- ZTS Nasdaq
- Market Cap
- CNI 64.6B
- ZTS 66.3B
- IPO Year
- CNI N/A
- ZTS 2013
- Fundamental
- Price
- CNI $92.57
- ZTS $147.36
- Analyst Decision
- CNI Buy
- ZTS Buy
- Analyst Count
- CNI 14
- ZTS 8
- Target Price
- CNI $119.11
- ZTS $204.00
- AVG Volume (30 Days)
- CNI 1.8M
- ZTS 3.8M
- Earning Date
- CNI 07-22-2025
- ZTS 08-05-2025
- Dividend Yield
- CNI 1.96%
- ZTS 1.36%
- EPS Growth
- CNI N/A
- ZTS 14.10
- EPS
- CNI 5.32
- ZTS 5.82
- Revenue
- CNI $12,569,471,933.00
- ZTS $9,385,000,000.00
- Revenue This Year
- CNI $2.97
- ZTS $3.63
- Revenue Next Year
- CNI $4.62
- ZTS $6.13
- P/E Ratio
- CNI $17.41
- ZTS $25.33
- Revenue Growth
- CNI 0.63
- ZTS 5.27
- 52 Week Low
- CNI $91.65
- ZTS $139.70
- 52 Week High
- CNI $121.12
- ZTS $200.33
- Technical
- Relative Strength Index (RSI)
- CNI 28.71
- ZTS 41.47
- Support Level
- CNI $92.41
- ZTS $144.25
- Resistance Level
- CNI $94.75
- ZTS $149.00
- Average True Range (ATR)
- CNI 1.30
- ZTS 3.72
- MACD
- CNI -0.22
- ZTS 0.03
- Stochastic Oscillator
- CNI 3.07
- ZTS 19.68
About CNI Canadian National Railway Company
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2024, CN generated CAD 17 billion in revenue by hauling intermodal containers (22% of consolidated revenue), petroleum and chemicals (20%), grain and fertilizers (20%), forest products (11%), metals and minerals (12%), automotive shipments (5%), and coal (5%). Other items constitute the remaining revenue.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.